Barts Health NHS Trust and local GPs Shared Care Guidelines. DENOSUMAB (Prolia) Post menopausal osteoporosis

Size: px
Start display at page:

Download "Barts Health NHS Trust and local GPs Shared Care Guidelines. DENOSUMAB (Prolia) Post menopausal osteoporosis"

Transcription

1 Barts Health NHS Trust and local GPs Shared Care Guidelines Indication: DENOSUMAB (Prolia) Post menopausal osteoporosis DOCUMENT TO BE SCANNED INTO ELECTRONIC RECORDS AS AND FILED IN NOTES Patient Name : Date of Birth: NHS No: Name of Referring Consultant: Contact number: INTRODUCTION Indication and Licensing Denosumab (Prolia) has been approved by NICE (NICE TA 204). Denosumab is licensed for the treatment of osteoporosis in postmenopausal women at increased risk of fractures. (NB It is also licensed for bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures). The recommended dose of Denosumab is 60mg administered as a single subcutaneous injection once every 6 months into the thigh, abdomen or back of the arm. Patients must be adequately supplemented with calcium and vitamin D. Primary Prevention Denosumab will be recommended as a treatment option for the primary prevention of osteoporotic fragility fractures only in postmenopausal women at increased risk of fractures: who are unable to comply with the special instructions for administering alendronate and either risedronate or etidronate, or have an intolerance of, or a contraindication to, those treatments and who have a combination of T-score, age and number of independent clinical risk factors for fracture. (Independent clinical risk factors for fractures are parental history of hip fracture, alcohol intake of 4 units or more per day, and rheumatoid arthritis). Secondary Prevention Denosumab will be recommended as a treatment option for the secondary prevention of osteoporotic fragility fractures only in postmenopausal women at increased risk of fractures who are unable to comply with the special instructions for administering alendronate and either risedronate or etidronate, or have an intolerance of, or a contraindication to, those treatments. Exclusions Patients with Stage 5 CKD are not be suitable for shared care

2 PATIENT PATHWAY- brief explanation of why planned arrangements for prescribing and monitoring between primary and secondary care are appropriate Denosumab is a straightforward subcutaneous injection given every 6 months. It does not require monitoring and has a favourable side-effect profile. It is therefore a suitable medication for initiation in secondary care and ongoing treatment in primary care. Patients are usually treated for 3 years in the first instance, but longer-term treatment may be necessary. Clinical Speciality / Indication Osteoporosis Prescribing Initiated by Prescribing Continued by Consultant GP to prescribe second Rheumatologist dose onwards First dose given in To be given at GP Osteoporosis clinic surgery Monitored by There is no specific monitoring required for Denosumab Duration of treatment Usually 3 years in the first instance After 3 years patient will be recalled to osteoporosis clinic automatically for review (follow-up appointment) The GP liase with the osteoporosis clinic after the treatment course or sooner if any concerns. The consultant will then assess and decide it treatment should be ongoing. DOSE AND ADMINISTRATION The recommended dose of denosumab is 60mg administered as a single subcutaneous injection once every 6 months into the thigh, abdomen or back of arm. Patient will receive an appropriate patient information leaflet from the osteoporosis clinic MONITORING STANDARDS FOR MEDICATION AT BARTS HEALTH NHS TRUST Pre-treatment Assessment (performed in secondary care) Hypocalcaemia is a contraindication and must be corrected before administration. Clinical monitoring of calcium levels is recommended for patients predisposed to hypocalcaemia. Check that the patient is calcium and vitamin D replete. Advise patients to seek prompt medical attention if they develop signs or symptoms of cellulitis. There are no other specific monitoring requirements for Denosumab. Before prescribing denosumab or intravenous bisphosphonates (MHRA advice): advise patients on precautions to take advise patients to: o tell their doctor if they have any problems with their mouth or teeth before starting treatment; if they wear dentures they should make sure their dentures fit properly before starting treatment o maintain good oral hygiene and get routine dental check-ups during treatment o tell their doctor and dentist that they are receiving denosumab or an intravenous bisphosphonate if they need dental treatment or dental surgery o tell their doctor and dentist immediately if they have any problems with their mouth or teeth during treatment (eg loose teeth, pain, swelling,non-healing sores or discharge. Monitoring during treatment Monitoring of calcium levels is only recommended for patients predisposed to hypocalcaemia (e.g. severe renal impairment or dialysis patients). Parameter Serum corrected calcium Target level Within normal range Frequency of monitoring Before each injection and 2 weeks after Action If hypocalcaemia to ensure patient is asymptomatic, increase calcium supplementation if

3 indicated and recheck 2 weeks later. KEY ADVERSE EFFECTS & ACTIONS Adverse effects Mild, transient decreases in serum calcium. Skin infections predominantly cellulitis. (Mechanisms uncertain) Other common undesirable effects (incidence of 1-10%) were urinary tract infection, upper respiratory tract infection, cataracts, constipation, sciatica, rash, pain in extremity. There have been no reports of anaphylaxis with the injection of Denosumab to date. Symptoms/signs (specify what would prompt action) Red, hot, inflamed skin Actions (what action should the GP take if identified in primary care) Treat with antibiotics/refer to on call medical team if IV treatment required Contra-indications (see BNF or SPC) Hypocalcaemia Hypersensitivity to the active substance or to any of the excipients Cautions (see BNF or SPC) Hypocalcaemia must be corrected by adequate intake of calcium and vitamin D before initiating therapy. Patients receiving Denosumab may develop skin infections (predominantly cellulitis). Patients must seek prompt medical attention if they develop signs of cellulitis. Osteonecrosis of the jaw (ONJ) has been reported (rare). A dental examination with appropriate preventive dentistry should be considered prior to starting Denosumab in patients with concomitant risk factors (a diagnosis of cancer with bone lesions, concomitant therapies {chemotherapy, corticosteroids, anti angiogenic biologics, radiotherapy to head and neck}, poor oral hygiene, dental extractions, and co-morbid disorders {pre-existing dental disease, anaemia, coagulopathy, infection} and previous treatment with bisphosphonates). While on Denosumab treatment patients should avoid invasive dental procedures and maintain good oral hygiene. There is no evidence to show when dental procedures should be performed if a patient is on treatment. Emergency dental treatment may be required during treatment, however if dental treatment can be planned it would be reasonable to plan this for the end of a 6 month treatment period and delay the next injection until the dental work has healed. Atypical femoral fractures have been reported in patients receiving Deonsumab. Atypical femoral fractures may occur with little or no trauma in the subtrochanteric and diaphyseal regions of the femur. Specific radiographic findings characterize these events. Atypical femoral fractures have also been reported in patients with certain comorbid conditions (e.g. vitamin D deficiency, rheumatoid arthritis, hypophosphatasia) and with use of certain pharmaceutical agents (e.g. bisphosphonates, glucocorticoids, proton pump inhibitors). These events have also occurred without antiresorptive therapy. Similar fractures reported in association with bisphosphonates are often bilateral; therefore the contralateral femur should be examined in Denosumab-treated patients who have sustained a femoral shaft fracture. Discontinuation of Denosumab therapy in patients suspected to have an atypical femur fracture should be considered pending evaluation of the patient based on an individual benefit risk assessment. During Denosumab treatment, patients should be advised to report new or unusual thigh, hip, or groin pain. Patients presenting with such symptoms should be evaluated for an incomplete femoral fracture. The needle cover of the prefilled syringe contains dry natural rubber (a derivative of latex), which may cause allergic reactions. Patients with rare hereditary problems of fructose intolerance should not use Denosumab.

4 Drug Interactions (see BNF or SPC) No interaction studies have been performed. This only lists the key important ADRs-For comprehensive information on cautions, contra-indications and interactions, please refer to the current British National Formulary and Summary of Product Characteristics. PREGNANCY AND BREAST FEEDING Denosumab(Prolia) is licenced for post-menopausal women only. For comprehensive information please refer to the current British National Formulary and Summary of Product Characteristics. SHARED CARE Role of Consultant 1. To assess the suitability of the patient for Denosumab. 2. To discuss the benefits and side effects of treatment with the patient, including guidance over dental surgery, ensuring that the patient/carer is an informed recipient in therapy and give the patient information leaflet (Appendix 1). 3. Ensure baseline investigations are normal before commencing treatment. 4. Explain to the patient that the treatment is 6 monthly injections for up to 3 years in the first instance. 5. Discuss the shared care arrangement with the patient and ensure he/she understands the plan for their follow-up 6 monthly injections at their GP surgery. 6. Explain to the patient that they will be recalled for follow-up in the osteoporosis clinic after 3 years of treatment and arrange that this happens. 7. Send a letter to the GP requesting shared care for this patient. 8. Ensure that the patient is taking calcium supplements (or has sufficient dietary calcium) and vitamin D supplements. 9. Assess the patient to ensure he/she has good oral hygiene and use clinical judgement to determine if dental examination is required prior to initiating therapy. 10. Initiate first Denosumab injection. 11. Evaluation of any reported adverse effects by GP or patient. 12. Report any adverse events to the MHRA. 13. Supply GP with a summary of the patient review and a copy of the local guidelines on use of Denosumab. 14. Ensure that backup advice is available at all times. 15. Identify patients that require monitoring for hypocalcaemia who will continue to receive prescribing,administration and monitoring from the hospital. 6.0 Role of General Practitioner 1. Reinforce the patients understanding of the nature, effect and potential side effects of the drug before prescribing it as part of the shared care programme and contact the specialist for clarification where appropriate, including guidance over dental surgery. 2. Monitor patient s overall health and well-being. 3. To ensure that Denosumab is added to the patient's drug record. 4. To ensure that other osteoporosis treatments (eg, alendronate, strontium) are stopped and removed from the patient's repeat prescription. 5. To ensure that calcium and vitamin D supplements are continued if appropriate. 6. Ensure an account is set up to order Denosumab and determine if it will come direct to the practice (more straightforward scenario for the patient). Alternatively, if the patient will need to collect their prescription from the pharmacy ensure an FP10 is written. 7. Ensure that prior to injection the Denosumab prefilled syringe must be kept in its outer carton, in order to protect from light, and stored in a refrigerator. 8. Prescribe and administer the Denosumab injection at six monthly intervals for time period as specified by the initiating specialist. 9. Report any adverse events to the MHRA and discuss with the consultant if action is uncertain. Role of Patient 1. To report any adverse events to the doctor who last administered the injection.

5 2. To seek prompt medical attention if they develop signs or symptoms of cellulitis. 3. To avoid invasive dental procedures and maintain good oral hygiene whilst on Denosumab treatment. 4. To continue the calcium and vitamin D supplement. 5. To attend the GP surgery every 6 months for the Denosumab injection. Costs Drug Product Denosumab (Prolia) 60mg sc injection Based on BNF edition March 2015 Cost in primary care 183 /syringe RESOURCES AVAILABLE Barts Health NHS Trust Consultant General Medical Registrar on-call out of hours Clinical Nurse Specialist Secretary at Whipps Cross (Mile End) Osteoporosis Office Mobile via switchboard Aircall via switchboard bleep via switchboard Whipps Cross bleep switchboard Mile End Rheumatology Pharmacist / bleep 975 Barts Health Medicines Information Pharmacist ext Prescribing Advice for Tower Hamlets CCG Prescribing Advice for Newham CCG Prescribing Advice for Waltham Forest CCG Prescribing Advice for Redbridge CCG /6 References Nice Guidance TA Pivotal Fracture study (Freedom trial) N Engl J Med Aug 20;361(8): doi: /NEJMoa Epub 2009 Aug 11. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. Cummings SR et al MHRA Drug Safety Update vol 12: Refer to the local CCG website to obtain the latest version of this guideline Updated template approved by Barts Health Joint Prescribing Group August 2015 (based on the document approved bybhr CCGMedicine Management Committee in July 2011) Guideline written by Dr Judith Bubbear, Consultant Rheumatologist, Review date: September 2018

6 Appendix 1 Patient Information Leaflet This reminder card contains important safety information that you need to be aware of before and during treatment with denosumab (Prolia). Your doctor has recommended that you receive denosumab (Prolia), which is used to treat osteoporosis and bone loss. These diseases involve thinning and weakening of the bones so they may break more easily. A side effect called osteonecrosis of the jaw (ONJ) (bone damage in the jaw) has been reported rarely (may affect up to 1 in 1,000 people) in patients receiving Prolia for osteoporosis. ONJ can also occur after stopping treatment. It is important to try to prevent ONJ developing as it may be a painful condition that can be difficult to treat. In order to reduce the risk of developing ONJ, there are some precautions you should take. Before starting treatment: Tell your doctor/nurse (health care professional) if you have any problems with your mouth or teeth. Your doctor may ask you to undergo a dental examination if you: were previously treated with a bisphosphonate are taking medicines called corticosteroids (such as prednisolone or dexamethasone) are a smoker have cancer have not had a dental check up for a long time have problems with your mouth or teeth While being treated: You should maintain good oral hygiene and receive routine dental check-ups. If you wear dentures you should make sure these fit properly. If you are under dental treatment or will undergo dental surgery (e.g. tooth extractions), inform your doctor and tell your dentist that you are being treated with Prolia. Contact your doctor and dentist immediately if you experience any problems with your mouth or teeth such as loose teeth, pain or swelling, or non-healing of sores or discharge, as these could be signs of osteonecrosis of the jaw Please read the package leaflet that comes with your medicine for further information. Reporting of side effects If you get any side effects talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet, You can also report side effects directly via the Yellow Card Scheme at By reporting side effects you can help provide more information on the safety of Prolia Electronic link to this leaflet below

7 Appendix 1 Barts Health NHS Trust (Chingford Osteoporosis Unit) Denosumab (Prolia) SHARED CARE AGREEMENT LETTER Name of GP. Address Dear GP Re: Patient s Name.. Date of Birth. Hospital Number... Indication for - Osteoporosis Route Subcutaneous Dose...60 mg 6 monthly. Enclosed is a copy of the shared care guidelines for Denosumab (Prolia) to be retained in the patient s notes. Should you agree to shared care, we will send a letter containing the details of the patient s treatment plan, the dose to be prescribed and all relevant blood results. Please sign below and return this letter to the Hospital Specialist if you agree to the shared care arrangements for this patient. Many thanks Hospital Specialist GP Signature... Signature... Name..... Name... Date... Date If you are not taking on shared care for this patient please state the reason why and return this letter to the Hospital Specialist..

DENOSUMAB SHARED CARE GUIDLINES

DENOSUMAB SHARED CARE GUIDLINES DENOSUMAB LICENSING Denosumab (PROLIA ) is licensed for the treatment of osteoporosis in postmenopausal women at increased risk of fractures and for bone loss associated with hormone ablation in men with

More information

Denosumab (Prolia 60 mg) Effective Shared Care Agreement For the treatment of Osteoporosis. Date: Date:

Denosumab (Prolia 60 mg) Effective Shared Care Agreement For the treatment of Osteoporosis. Date: Date: Denosumab (Prolia 60 mg) Effective Shared Care Agreement For the treatment of Osteoporosis Section 1: Shared care arrangements and responsibilities Section 1.1 Agreement for transfer of prescribing to

More information

S H A R E D C A R E G U I D E L I N E Drug: Denosumab 60mg injection Indication: treatment of osteoporosis in postmenopausal women

S H A R E D C A R E G U I D E L I N E Drug: Denosumab 60mg injection Indication: treatment of osteoporosis in postmenopausal women S H A R E D C A R E G U I D E L I N E Drug: Denosumab 60mg injection Indication: treatment of osteoporosis in postmenopausal women Introduction Indication: Denosumab (Prolia ) is recommended in NICE TA204

More information

Administration of Denosumab (PROLIA ) for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures

Administration of Denosumab (PROLIA ) for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures Administration of Denosumab (PROLIA ) for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures 2017 18 1. Purpose of Agreement This agreement outlines the expectations

More information

Guidance for the administration of Denosumab (Prolia ) in Primary Care GENERAL INFORMATION should be recommended

Guidance for the administration of Denosumab (Prolia ) in Primary Care GENERAL INFORMATION should be recommended Guidance for the administration of Denosumab (Prolia ) in Primary Care GENERAL INFORMATION Denosumab is suitable for patients with established osteoporosis for both primary and secondary fracture prevention

More information

Denosumab for the treatment of osteoporosis in postmenopausal women at increased risk of fractures

Denosumab for the treatment of osteoporosis in postmenopausal women at increased risk of fractures APper apc15-0avgfh7 Shared Care Guideline Denosumab for the treatment of osteoporosis in postmenopausal women at increased risk of fractures For the latest information on interactions and adverse effects,

More information

ESCA: Denosumab for the treatment of osteoporosis in postmenopausal women.

ESCA: Denosumab for the treatment of osteoporosis in postmenopausal women. ESCA: Denosumab for the treatment of osteoporosis in postmenopausal women. Specialist details Patient identifier Name Tel: This effective shared care agreement (ESCA) sets out details for the sharing of

More information

Greater Manchester Interface Prescribing Group Shared Care Template

Greater Manchester Interface Prescribing Group Shared Care Template Greater Manchester Interface Prescribing Group Shared Care Template Shared Care Guideline the use of Denosumab for the prevention of osteoporotic fractures in postmenopausal women. Author(s)/Originator(s):

More information

Denosumab (Prolia ) (TLS Amber)

Denosumab (Prolia ) (TLS Amber) Denosumab (Prolia ) (TLS Amber) Shared Care Guidelines: For the treatment of postmenopausal osteoporosis. AREAS OF RESPONSIBILITY FOR THE SHARING OF CARE This shared care agreement outlines suggested ways

More information

Adding Prolia (denosumab) to EMIS Web

Adding Prolia (denosumab) to EMIS Web Prescribing information can be found on page 15 Adding Prolia (denosumab) to EMIS Web Date of preparation September 2013 DMB-GBR-AMG-597-2013-P UK/DNB/0083c/13 37046242 Amgen & GSK have fully funded the

More information

Adding Prolia (denosumab) to SystmOne

Adding Prolia (denosumab) to SystmOne Prescribing information can be found on page 15 Adding Prolia (denosumab) to SystmOne Date of preparation September 2013 DMB-GBR-AMG-594-2013-P UK/DNB/0083/13 37046251 Amgen & GSK have fully funded the

More information

Adding Prolia (denosumab) to INPS Vision

Adding Prolia (denosumab) to INPS Vision Prescribing information can be found on page 15 Adding Prolia (denosumab) to INPS Vision Date of preparation September 2013 DMB-GBR-AMG-598-2013-P UK/DNB/0083d/13 37046239 Amgen & GSK have fully funded

More information

Adding Prolia (denosumab) to EMIS PCS

Adding Prolia (denosumab) to EMIS PCS Prescribing information can be found on page 15 Adding Prolia (denosumab) to EMIS PCS Date of preparation October 2014 DMB-GBR-AMG-658-2014-P Amgen have fully funded the development, by Oberoi Consulting,

More information

Adding Prolia (denosumab) to EMIS PCS

Adding Prolia (denosumab) to EMIS PCS Prescribing information can be found on page 15 Adding Prolia (denosumab) to EMIS PCS Date of preparation July 2015 UKIE-P-162-0615-108159 Amgen have fully funded the development, by Oberoi Consulting,

More information

Prescribing Framework for Denosumab (Prolia ) in Osteoporosis

Prescribing Framework for Denosumab (Prolia ) in Osteoporosis Hull & East Riding Prescribing Committee Prescribing Framework for Denosumab (Prolia ) in Osteoporosis Patients Name:.. NHS Number: Patients Address:... (Use addressograph sticker) Communication We agree

More information

Adding Prolia (denosumab) to INPS Vision

Adding Prolia (denosumab) to INPS Vision Prescribing information can be found on page 19 Adding Prolia (denosumab) to INPS Vision Date of preparation July 2015 UKIE-P-162-0615-108161 Amgen have fully funded the development, by Oberoi Consulting,

More information

Rheumatology Department Patient Information Leaflet. Introduction Prolia (denosumab) is a treatment for post-menopausal osteoporosis.

Rheumatology Department Patient Information Leaflet. Introduction Prolia (denosumab) is a treatment for post-menopausal osteoporosis. Prolia (denosumab) Rheumatology Department Patient Information Leaflet Introduction Prolia (denosumab) is a treatment for post-menopausal osteoporosis. What is osteoporosis? Osteoporosis is a condition

More information

Prescribing of Denosumab (Prolia ) in Wales: Review. Full document

Prescribing of Denosumab (Prolia ) in Wales: Review. Full document Prescribing of Denosumab (Prolia ) in Wales: Review Full document October 2013 This report has been prepared by a multiprofessional collaborative group, with support from the All Wales Prescribing Advisory

More information

Summary of the risk management plan by product

Summary of the risk management plan by product Summary of the risk management plan by product 1 Elements for summary tables in the EPAR 1.1 Summary table of Safety concerns Summary of safety concerns Important identified risks Important potential risks

More information

Adding Prolia (denosumab) to EMIS Web

Adding Prolia (denosumab) to EMIS Web Prescribing information can be found on page 19 Adding Prolia (denosumab) to EMIS Web Date of preparation: August 2017 UKIE-P-162-0616-031936(1) Amgen have fully funded the development, by Oberoi Consulting,

More information

Adding Prolia (denosumab) to INPS Vision

Adding Prolia (denosumab) to INPS Vision Prescribing information can be found on page 19 Adding Prolia (denosumab) to INPS Vision Date of preparation October 2014 DMB-GBR-AMG-661-2014-P Amgen have fully funded the development, by Oberoi Consulting,

More information

Oxford University Hospitals Guidelines for Adjuvant Bisphosphonate treatment for Post-Menopausal Women with Early Breast Cancer

Oxford University Hospitals Guidelines for Adjuvant Bisphosphonate treatment for Post-Menopausal Women with Early Breast Cancer Oxford University Hospitals Guidelines for Adjuvant Bisphosphonate treatment for Post-Menopausal Women with Early Breast Cancer Category: Summary: Guideline Adjuvant Bisphosphonate treatment for Post-Menopausal

More information

Bisphosphonates Length of treatment in osteoporosis in primary care- Treatment holiday

Bisphosphonates Length of treatment in osteoporosis in primary care- Treatment holiday Bisphosphonates Length of treatment in osteoporosis in primary care- Treatment holiday This guidance incorporate National Osteoporosis Guideline Group (NOGG) guidance March 2017 Clinical guideline for

More information

Adding Prolia (denosumab) to SystmOne

Adding Prolia (denosumab) to SystmOne Prescribing information can be found on page 19 Adding Prolia (denosumab) to SystmOne Date of preparation October 2014 DMB-GBR-AMG-662-2014-P Amgen have fully funded the development, by Oberoi Consulting,

More information

1231 Zoledronic acid in early breast cancer Page 1 of 5

1231 Zoledronic acid in early breast cancer Page 1 of 5 Zoledronic acid in early breast cancer Zoledronic acid in early breast cancer Zoledronic acid is a bisphosphonate. This is treatment which works by slowing down the rate of bone change. In the bone there

More information

Zerlinda (MRP DK/H/2265/001)

Zerlinda (MRP DK/H/2265/001) Zerlinda (MRP DK/H/2265/001) VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Prevention of bone complications, e.g. fractures, in adult patients with bone metastases (spread

More information

Prolia 2 shots a year proven to help strengthen bones. next shot appointment

Prolia 2 shots a year proven to help strengthen bones. next shot appointment Ask your doctor if Prolia (denosumab) is right for you and visit us at www.prolia.com next shot appointment For women with postmenopausal osteoporosis at high risk for fracture: there s Prolia. Prolia

More information

PHYSICIAN OFFICE BILLING INFORMATION SHEET FOR XGEVA. Notes

PHYSICIAN OFFICE BILLING INFORMATION SHEET FOR XGEVA. Notes For prevention of skeletal-related events XGEVA is indicated for the prevention of skeletal-related events in patients with bone metastases from solid tumors. XGEVA is not indicated for the prevention

More information

Osteoporosis Clinical Guideline. Rheumatology January 2017

Osteoporosis Clinical Guideline. Rheumatology January 2017 Osteoporosis Clinical Guideline Rheumatology January 2017 Introduction Osteoporosis is a condition of low bone mass leading to an increased risk of low trauma fractures. The prevalence of osteoporosis

More information

Clodronate BE/H/PSUR/001/001 October 2011 Agreed CSP

Clodronate BE/H/PSUR/001/001 October 2011 Agreed CSP Clodronate BE/H/PSUR/001/001 October 2011 Agreed CSP 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Intravenous use Treatment of hypercalcemia due to malignancy. Oral use Treatment of hypercalcemia

More information

Osteoporosis Update. Greg Summers Consultant Rheumatologist

Osteoporosis Update. Greg Summers Consultant Rheumatologist Osteoporosis Update Greg Summers Consultant Rheumatologist DEFINITION OSTEOPOROSIS is LOW BONE MASS (& micro-architectural deterioration) causing AN INCREASED RISK OF FRACTURE 23 years 82 years 23 y/o

More information

MELATONIN Insomnia and Sleep Disorders in Children

MELATONIN Insomnia and Sleep Disorders in Children DOCUMENT TO BE SCANNED INTO ELECTRONIC RECORDS AS AND FILED IN NOTES Patient Name : Date of Birth: NHS No: Name of Referring Consultant: Contact number: INTRODUCTION Melatonin is a pineal hormone which

More information

Clinical Specialist Statement Template

Clinical Specialist Statement Template Clinical Specialist Statement Template Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can

More information

Prolia 2 shots a year proven to help strengthen bones.

Prolia 2 shots a year proven to help strengthen bones. For women with postmenopausal osteoporosis at high risk for fracture: there s Prolia. Prolia 2 shots a year proven to help strengthen bones. Blythe Danner, Award winning actress taking Prolia. Prolia is

More information

Elements for a Public Summary

Elements for a Public Summary Ibandronat Stada 50 mg film-coated tablets Ibandronat Stada 150 mg film-coated tablets 3.11.2014, Version V2.1 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN VI.2 Elements for a Public Summary

More information

Prolia 2 shots a year proven to help strengthen bones.

Prolia 2 shots a year proven to help strengthen bones. Ask your doctor if Prolia (denosumab) is right for you and visit us at www.prolia.com For women with postmenopausal osteoporosis at high risk for fracture: there s Prolia. Prolia 2 shots a year proven

More information

Package leaflet: Information for the user. Ibandroninezuur STADA 3 mg/3 ml, oplossing voor injectie. Ibandronic acid

Package leaflet: Information for the user. Ibandroninezuur STADA 3 mg/3 ml, oplossing voor injectie. Ibandronic acid Package leaflet: Information for the user Ibandroninezuur STADA 3 mg/3 ml, oplossing voor injectie Ibandronic acid Read all of this leaflet carefully before you start using this medicine because it contains

More information

Costing statement: Denosumab for the prevention of osteoporotic fractures in postmenopausal women

Costing statement: Denosumab for the prevention of osteoporotic fractures in postmenopausal women Costing statement: Denosumab for the prevention of osteoporotic fractures in postmenopausal women Resource impact The guidance Denosumab for the prevention of osteoporotic fractures in postmenopausal women

More information

Rivaroxaban film coated tablets are available in 2 strengths for this indication: 15mg and 20mg.

Rivaroxaban film coated tablets are available in 2 strengths for this indication: 15mg and 20mg. Primary Care Prescriber Information RIVAROXABAN (XARELTO ) Treatment of acute venous thromboembolism and prevention of recurrent venous thromboembolism INDICATION Rivaroxaban is a non-vitamin K antagonist

More information

MAN SHORTER CAN MAKE A HOW OSTEOPOROSIS. Ask your doctor if you have osteoporosis and if Prolia may be right for you. AND WHAT YOU CAN DO NEXT

MAN SHORTER CAN MAKE A HOW OSTEOPOROSIS. Ask your doctor if you have osteoporosis and if Prolia may be right for you. AND WHAT YOU CAN DO NEXT Ask your doctor if you have osteoporosis and if Prolia may be right for you. Prolia is a prescription medicine used to increase bone mass in men with osteoporosis who: are at high risk for fracture, meaning

More information

Horizon Scanning Centre March Denosumab for glucocorticoidinduced SUMMARY NIHR HSC ID: 6329

Horizon Scanning Centre March Denosumab for glucocorticoidinduced SUMMARY NIHR HSC ID: 6329 Horizon Scanning Centre March 2014 Denosumab for glucocorticoidinduced osteoporosis SUMMARY NIHR HSC ID: 6329 This briefing is based on information available at the time of research and a limited literature

More information

ESCA: Cinacalcet (Mimpara )

ESCA: Cinacalcet (Mimpara ) ESCA: Cinacalcet (Mimpara ) Effective Shared Care Agreement for the Treatment of Primary hyperparathyroidism when parathyroidectomy is contraindicated or not clinically appropriate. Specialist details

More information

SOMATROPIN ( Genotropin, Humatrope, Norditropin,

SOMATROPIN ( Genotropin, Humatrope, Norditropin, Shared Care Guidelines DRUG: SOMATROPIN ( Genotropin, Humatrope, Norditropin, Saizen and Omnitrope ) (Adults) Introduction: Indication: Growth hormone deficiency in adults Dosage & administration: 150-300

More information

FOSAMAX (Alendronic acid as alendronate sodium trihydrate)

FOSAMAX (Alendronic acid as alendronate sodium trihydrate) CSP - UK/H/PSUR/0070 - March 2012 EUROPEAN UNION CORE SAFETY PROFILE FOSAMAX (Alendronic acid as alendronate sodium trihydrate) 4.2 Posology and method of administration The recommended dosage is one 70

More information

Bisphosphonate treatment break

Bisphosphonate treatment break Bulletin 110 December 2015 Bisphosphonate treatment break Bisphosphonates have been widely used in the treatment of osteoporosis with robust data demonstrating efficacy in fracture risk reduction over

More information

BONIVA (ibandronate sodium)

BONIVA (ibandronate sodium) BONIVA (ibandronate sodium) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices

More information

Degarelix Subcutaneous Injection (Firmagon ) Treatment Guideline

Degarelix Subcutaneous Injection (Firmagon ) Treatment Guideline Mid Essex Locality Degarelix Subcutaneous Injection (Firmagon ) Treatment Guideline Contents FlowChart 2 Summary... 3 Key points... 3 Introduction... 3 Pharmacology... 3 Product information... 4 Place

More information

Osteoporosis challenges

Osteoporosis challenges Osteoporosis challenges Osteoporosis challenges Who should have a fracture risk assessment? Who to treat? Drugs, holidays and unusual adverse effects Fracture liaison service? The size of the problem 1

More information

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 21 July 2010

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 21 July 2010 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 21 July 2010 Review of the dossier of the medicinal product included on the list of reimbursable medicines for a period

More information

Package leaflet: Information for the user. Zoledronic Acid Accord 4 mg/5 ml concentrate for solution for infusion Zoledronic acid

Package leaflet: Information for the user. Zoledronic Acid Accord 4 mg/5 ml concentrate for solution for infusion Zoledronic acid Package leaflet: Information for the user Zoledronic Acid Accord 4 mg/5 ml concentrate for solution for infusion Zoledronic acid Read all of this leaflet carefully before you start taking this medicine

More information

SHARED CARE PRESCRIBING GUIDELINE AZATHIOPRINE IN ADULT PATIENTS WITH RHEUMATOID ARTHRITIS DOCUMENT DETAILS

SHARED CARE PRESCRIBING GUIDELINE AZATHIOPRINE IN ADULT PATIENTS WITH RHEUMATOID ARTHRITIS DOCUMENT DETAILS SHARED CARE PRESCRIBING GUIDELINE AZATHIOPRINE IN ADULT PATIENTS WITH RHEUMATOID ARTHRITIS DOCUMENT DETAILS Document type Shared Care Prescribing Guideline Document name Shared Care Prescribing Guideline:

More information

Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS.

Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Appendix I - Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can provide a unique perspective

More information

Prolia Denosumab(rch) den''-os''-u''-mab Consumer Medicine Information (CMI)

Prolia Denosumab(rch) den''-os''-u''-mab Consumer Medicine Information (CMI) Prolia Denosumab(rch) den''-os''-u''-mab Consumer Medicine Information (CMI) What is in this CMI What Prolia is used for When you must not be given it Taking other medicines How it is given Instructions

More information

Bonefos 400 mg capsules sodium clodronate

Bonefos 400 mg capsules sodium clodronate Due to regulatory changes, the content of the following Patient Information Leaflet may vary from the one found in your medicine pack. Please compare the 'Leaflet prepared/revised date' towards the end

More information

Denosumab for the prevention of osteoporotic fractures in postmenopausal women

Denosumab for the prevention of osteoporotic fractures in postmenopausal women Denosumab for the prevention of osteoporotic fractures in Issued: October 2010 guidance.nice.org.uk/ta204 NICE has accredited the process used by the Centre for Health Technology Evaluation at NICE to

More information

INTRODUCTION Indication and Licensing

INTRODUCTION Indication and Licensing City and Hackney Clinical Commissioning Group Homerton University Hospital Foundation Trust DRUG NAME: Apixaban (Eliquis ) Transfer of Care document Indication: Treatment of acute venous thromboembolism

More information

Dumfries and Galloway. Treatment Protocol for Osteoporosis

Dumfries and Galloway. Treatment Protocol for Osteoporosis Dumfries and Galloway Treatment Protocol for Osteoporosis DIAGNOSIS OF OSTEOPOROSIS 2 Diagnostic Criteria 2 REFERRAL CRITERIA FOR DEXA 3 TREATMENT 4 Non-Drug Therapy : for all 4 Non-Drug Therapy : in the

More information

SULFASALAZINE (Adults)

SULFASALAZINE (Adults) Shared Care Guideline DRUG: Introduction: SULFASALAZINE (Adults) Indication: Disease modifying drug for rheumatoid arthritis, psoriatic arthritis, undifferentiated arthritis, spondyloarthropathies, Crohn

More information

Package leaflet: Information for the patient. Risedronate sodium 35 mg film-coated tablets. Risedronate sodium

Package leaflet: Information for the patient. Risedronate sodium 35 mg film-coated tablets. Risedronate sodium Package leaflet: Information for the patient Risedronate sodium 35 mg film-coated tablets Risedronate sodium Read all of this leaflet carefully before you start taking this medicine because it contains

More information

SHARED CARE PRESCRIBING GUIDELINE LEFLUNOMIDE IN ADULT PATIENTS WITH RHEUMATOID ARTHRITIS DOCUMENT DETAILS

SHARED CARE PRESCRIBING GUIDELINE LEFLUNOMIDE IN ADULT PATIENTS WITH RHEUMATOID ARTHRITIS DOCUMENT DETAILS SHARED CARE PRESCRIBING GUIDELINE LEFLUNOMIDE IN ADULT PATIENTS WITH RHEUMATOID ARTHRITIS DOCUMENT DETAILS Document type Shared Care Prescribing Guideline Document name Shared Care Prescribing Guideline:

More information

Primary Care Prescriber Information EDOXABAN (LIXIANA ) Treatment of acute venous thromboembolism and prevention of recurrent venous thromboembolism

Primary Care Prescriber Information EDOXABAN (LIXIANA ) Treatment of acute venous thromboembolism and prevention of recurrent venous thromboembolism Primary Care Prescriber Information EDOXABAN (LIXIANA ) Treatment of acute venous thromboembolism and prevention of recurrent venous thromboembolism INDICATION Edoxaban is a non-vitamin K antagonist oral

More information

Fulvestrant (Faslodex )

Fulvestrant (Faslodex ) In Partnership with Health Authorities & GPs continuing-care guidelines Fulvestrant (Faslodex ) in the Management of Postmenopausal Women with Advanced Breast Cancer Approved by: Date approved: October

More information

Osteoporosis Agents Drug Class Prior Authorization Protocol

Osteoporosis Agents Drug Class Prior Authorization Protocol Osteoporosis Agents Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of

More information

Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM ZOLEDRONIC ACID. Patient s first names.

Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM ZOLEDRONIC ACID. Patient s first names. Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM ZOLEDRONIC ACID Patient s surname/family name Patient s first names Date of birth NHS number (or other identifier)

More information

AACE/ACE Osteoporosis Treatment Decision Tool

AACE/ACE Osteoporosis Treatment Decision Tool AACE/ACE Osteoporosis Treatment Decision Tool What is Osteoporosis? OSTEOPOROSIS is defined as reduced bone strength leading to an increased risk of fracture. Osteoporosis, or porous bones, occurs when

More information

Denosumab for the prevention of osteoporotic fractures in postmenopausal women

Denosumab for the prevention of osteoporotic fractures in postmenopausal women Issue date: October 2010 Denosumab for the prevention of osteoporotic fractures in postmenopausal women This guidance was developed using the single technology appraisal process NICE technology appraisal

More information

Oral Health Management of Patients at Risk of Medication-related Osteonecrosis of the Jaw Guidance in Brief

Oral Health Management of Patients at Risk of Medication-related Osteonecrosis of the Jaw Guidance in Brief Oral Health Management of Patients at Risk of Medication-related Osteonecrosis of the Jaw Guidance in Brief For further details, please refer to the full guidance, available at www.sdcep.org.uk March 2017

More information

Hydroxychloroquine (Adults)

Hydroxychloroquine (Adults) Shared Care Guideline DRUG: Introduction: Contraindications & Warnings: Hydroxychloroquine (Adults) Indication: Rheumatoid arthritis and inflammatory osteoarthritis, discoid and systemic lupus erythematosus,

More information

IMPORTANT: PLEASE READ

IMPORTANT: PLEASE READ PART III: CONSUMER INFORMATION Pr Zoledronic Acid A (zoledronic acid injection) for intravenous infusion This leaflet is part III of a three-part "Product Monograph" published when Zoledronic Acid A was

More information

PART III: CONSUMER INFORMATION

PART III: CONSUMER INFORMATION PART III: CONSUMER INFORMATION Pr ACLASTA (zoledronic acid injection) for intravenous infusion This leaflet is part III of a three-part "Product Monograph" published when ACLASTA was approved for sale

More information

IMPORTANT: PLEASE READ

IMPORTANT: PLEASE READ PART III: CONSUMER INFORMATION Pr Zoledronic Acid A (zoledronic acid injection) for intravenous infusion This leaflet is part III of a three-part "Product Monograph" published when Zoledronic Acid A was

More information

Medicines Management Group

Medicines Management Group SHARED CARE PROTOCOL for FULVESTRANT (FASLODEX ) INJECTION Scope Fulvestrant may be considered for shared care arrangements for the treatment of metastatic breast cancer for disease relapse. Unique Identifier

More information

Pathway from Fracture or Risk Factor to Treatment

Pathway from Fracture or Risk Factor to Treatment Appendix 6A - Guidance on Diagnosis and Management of Osteoporosis Pathway from Fracture or Risk Factor to Treatment Fragility Fracture = fracture sustained from a low energy fall from standing height

More information

Prescribing Framework for Methotrexate for Immunosuppression in ADULTS

Prescribing Framework for Methotrexate for Immunosuppression in ADULTS Hull & East Riding Prescribing Committee Prescribing Framework for Methotrexate for Immunosuppression in ADULTS Patient s Name:.. NHS Number: Patient s Address:... (Use addressograph sticker) GP s Name:...

More information

Name of Shared Care Agreement: AZATHIOPRINE/6-MERCAPTOPURINE: Oral immunomodulating drugs for inflammatory bowel disease. Reference number: 01/2008

Name of Shared Care Agreement: AZATHIOPRINE/6-MERCAPTOPURINE: Oral immunomodulating drugs for inflammatory bowel disease. Reference number: 01/2008 Name of Shared Care Agreement: AZATHIOPRINE/6-MERCAPTOPURINE: Oral immunomodulating drugs for inflammatory bowel disease. Reference number: 01/2008 Shared care agreement has been developed appropriately

More information

Primary Care Prescriber Information RIVAROXABAN (XARELTO ) Prevention of stroke and embolism for nonvalvular atrial fibrillation

Primary Care Prescriber Information RIVAROXABAN (XARELTO ) Prevention of stroke and embolism for nonvalvular atrial fibrillation Primary Care Prescriber Information RIVAROXABAN (XARELTO ) Prevention of stroke and embolism for nonvalvular atrial fibrillation INDICATION Rivaroxaban is a non-vitamin K antagonist oral anticoagulant

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Prolia 60 mg solution for injection in a pre-filled syringe 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each pre-filled syringe

More information

Western Locality Shared care Information ~ Penicillamine, Rheumatology April 2013

Western Locality Shared care Information ~ Penicillamine, Rheumatology April 2013 Western Locality Shared care Information ~ Penicillamine, Rheumatology April 2013 Penicillamine Treatment of: Rheumatoid arthritis Specialist: Please complete the Shared Care letter sending a request to

More information

SHARED CARE PRESCRIBING GUIDELINE

SHARED CARE PRESCRIBING GUIDELINE WORKING IN PARTNERSHIP East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG, Surrey Heath CCG, North East Hampshire & Farnham CCG, Crawley CCG, Horsham & Mid-Sussex CCG SHARED

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. Risedronat Jubilant 5 mg film-coated tablets risedronate sodium

PACKAGE LEAFLET: INFORMATION FOR THE USER. Risedronat Jubilant 5 mg film-coated tablets risedronate sodium PACKAGE LEAFLET: INFORMATION FOR THE USER Risedronat Jubilant 5 mg film-coated tablets risedronate sodium Read all of this leaflet carefully before you start taking this medicine because it contains important

More information

Buccal Midazolam For the treatment of prolonged epileptic seizures, clusters of epileptic seizures and status epilepticus.

Buccal Midazolam For the treatment of prolonged epileptic seizures, clusters of epileptic seizures and status epilepticus. Oxfordshire Clinical Commissioning Group, Oxford University Hospitals NHS Trust and Oxfordshire Health NHS Foundation Trust Shared Care Protocol and Information for GPs Buccal Midazolam For the treatment

More information

Shared Care Agreement for Donepezil

Shared Care Agreement for Donepezil ESCA: for the treatment of Alzheimer s disease SECONDARY CARE SECTION TO BE COMPLETED BY INITIATING DOCTOR Patient s Name: Date of Birth: NHS Number: ESCA Date: One copy of information leaflet given to

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. Risedronat Jubilant 35 mg film-coated tablets risedronate sodium

PACKAGE LEAFLET: INFORMATION FOR THE USER. Risedronat Jubilant 35 mg film-coated tablets risedronate sodium PACKAGE LEAFLET: INFORMATION FOR THE USER Risedronat Jubilant 35 mg film-coated tablets risedronate sodium Read all of this leaflet carefully before you start taking this medicine because it contains important

More information

Osteonecrosis of the jaw (ONJ)

Osteonecrosis of the jaw (ONJ) Osteonecrosis of the jaw (ONJ) This Infosheet explains what osteonecrosis of the jaw (ONJ) is, a rare condition related to long-term treatment with drugs known as bisphosphonates. What is ONJ? ONJ is a

More information

Understanding bone metastases and XGEVA

Understanding bone metastases and XGEVA Understanding bone metastases and XGEVA Contents About bone metastases 3 About XGEVA 5 Dealing with common side effects of XGEVA 8 FAs about living with bone metastases 9 Notes 10 About bone metastases

More information

Technology appraisal guidance Published: 9 August 2017 nice.org.uk/guidance/ta464

Technology appraisal guidance Published: 9 August 2017 nice.org.uk/guidance/ta464 Bisphosphonates for treating osteoporosis Technology appraisal guidance Published: 9 August 2017 nice.org.uk/guidance/ta464 NICE 2017. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).

More information

Primary Care Prescriber Information EDOXABAN (LIXIANA ) Prevention of stroke and embolism for nonvalvular atrial fibrillation

Primary Care Prescriber Information EDOXABAN (LIXIANA ) Prevention of stroke and embolism for nonvalvular atrial fibrillation Primary Care Prescriber Information EDOXABAN (LIXIANA ) Prevention of stroke and embolism for nonvalvular atrial fibrillation INDICATION Edoxaban is a non-vitamin K antagonist oral anticoagulant (NOAC)

More information

Summary. Background. Diagnosis

Summary. Background. Diagnosis March 2009 Management of post-menopausal osteoporosis This bulletin focuses on the pharmacological management of patients with post-menopausal osteoporosis both those with clinically evident disease (e.g.

More information

Page 1

Page 1 Osteoporosis Osteoporosis is a condition characterised by weakened bones that fracture easily. After menopause many women are at risk of developing osteoporosis. Peak bone mass is usually reached during

More information

Prolia Denosumab(rch) den''-os''-u''-mab Consumer Medicine Information (CMI)

Prolia Denosumab(rch) den''-os''-u''-mab Consumer Medicine Information (CMI) Prolia Denosumab(rch) den''-os''-u''-mab Consumer Medicine Information (CMI) What is in this CMI What Prolia is used for When you must not be given it Taking other medicines How it is given Instructions

More information

Prescribing Framework for Mycophenolate Mofetil or Mycophenolic Acid (Myfortic ) Post Solid Organ Transplant

Prescribing Framework for Mycophenolate Mofetil or Mycophenolic Acid (Myfortic ) Post Solid Organ Transplant Hull & East Riding Prescribing Committee Prescribing Framework for Mycophenolate Mofetil or Mycophenolic Acid (Myfortic ) Post Solid Organ Transplant Patient s Name:.. NHS Number: Patient s Address:...

More information

APOMORPHINE (Adults) Shared Care Guidelines DRUG:

APOMORPHINE (Adults) Shared Care Guidelines DRUG: Shared Care Guidelines DRUG: APOMORPHINE (Adults) Indication: Treatment of motor fluctuations in patients with Parkinson's disease which is not sufficiently controlled by oral anti-parkinson medication.

More information

PATIENT GROUP DIRECTION. Oral (live attenuated) Typhoid Vaccine (Ty21a) (Vivotif )

PATIENT GROUP DIRECTION. Oral (live attenuated) Typhoid Vaccine (Ty21a) (Vivotif ) PATIENT GROUP DIRECTION Administration of: Oral (live attenuated) Typhoid Vaccine (Ty21a) (Vivotif ) By: Practice Nurses In: General Practice It is the responsibility of the professional working under

More information

SHARED CARE AGREEMENT: MELATONIN (CHILDREN)

SHARED CARE AGREEMENT: MELATONIN (CHILDREN) NB: This document should be read in conjunction with the current Summary of Product Characteristics (SPC) where appropriate. DRUG AND INDICATION: Generic drug name: Formulations: MELATONIN 3mg immediate

More information

DRUG: Introduction. `Shared Care Guidelines. They can also be used long term for chronic pulmonary Pseudomonas aeruginosa infection.

DRUG: Introduction. `Shared Care Guidelines. They can also be used long term for chronic pulmonary Pseudomonas aeruginosa infection. `Shared Care Guidelines DRUG: Introduction Inhaled antibiotics (Adults and Paediatrics) in Cystic Fibrosis. EXISTING ESTABLISHED PATIENTS ONLY Colistimethate (Colomycin, Promixin ) Tobramycin (Tobi Bramitob

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Prolia 60 mg solution for injection in pre-filled syringe 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each pre-filled syringe

More information

Pharmacy Management Drug Policy

Pharmacy Management Drug Policy SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 9/29/2017 If the member s subscriber contract excludes coverage

More information

Vol. 19, Bulletin No. 108 August-September 2012 Also in the Bulletin: Denosumab 120mg for Bone Metastases

Vol. 19, Bulletin No. 108 August-September 2012 Also in the Bulletin: Denosumab 120mg for Bone Metastases ה מ ר א פ הביטאון לענייני תרופות ISRAEL DRUG BULLETIN 19 years of unbiased and independent drug information P H A R x M A Vol. 19, Bulletin No. 108 August-September 2012 Also in the Bulletin: Denosumab

More information